NCT05865171View on ClinicalTrials.gov

A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

June 12, 2023

Primary Completion Date

June 12, 2024

Study Completion Date

June 12, 2024

Conditions

Renal Impairment

Interventions

DRUG

IXP

Tablets for oral administration.

Trial Locations (2)

33603

Genesis Clinical Research, Tampa

34471

GCP Research, Ocala

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY